Clinical Trial

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-01-04; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2024-08-18
Status change: Not Yet Recruiting → Recruiting 2022-03-22
Trial Details
NCT Number NCT05194995
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
Enrollment 48 participants
Start Date 2022-02-17
Primary Completion 2025-04-30 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-16